Next week (19th-23rd), four corporations, including d'Alba Global, will enter the stock market. The wire manufacturing corporation Kistron is preparing for a public offering, while GC Genome and SYNIC Solution will conduct demand forecasting.
According to the financial investment industry on the 18th, d'Alba Global, known for its cosmetics brand "d'Alba," will be listed on the Korea Exchange on the 22nd. The offering price is 63,000 won, and the expected market capitalization after listing is around 800 billion won.
d'Alba Global was founded in 2016 by CEO Byeon Seong-yeon, who previously worked as a consultant for cosmetics corporate business strategy. Gaining popularity with its "Crew Mist," the company recorded an operating profit of 59.8 billion won last year.
ImmuneOncia (19th) and Biobijou (20th), along with IntoCell (23rd), will be listed on the KOSDAQ market.
Founded in 2016 as a joint venture between Yuhan Corporation and Sorrento Therapeutics, ImmuneOncia specializes in developing immune oncology drugs targeting immune cells such as T cells and macrophages.
Biobijou, established in 2018, develops, manufactures, and sells various medical beauty products, including skin boosters and hyaluronic acid (HA) fillers.
IntoCell is an antibody-drug conjugate (ADC) platform research and development corporation founded in 2015. ADC is a next-generation anticancer drug formed by a chemical bond through a linker connecting an antibody that targets cancer cells and a payload that destroys cancer cells.
Alongside this, Kistron will accept public subscription applications from general investors on the 22nd to 23rd. Kistron is a subsidiary of the KISWIRE group, established in 1992, and its main business is the manufacture of copper wire with iron core.
GC Genome (19th-23rd) and SYNIC Solution (22nd-28th) will conduct demand forecasting for institutional investors to finalize the offering price.
Established as a subsidiary of GC Biopharma in 2013, GC Genome is a clinical genome analysis specialized corporation providing over 300 types of genetic testing services, including health examination tests, prenatal and newborn tests, precision diagnostic tests for cancer, and precision diagnostic tests for genetic rare diseases.
SYNIC Solution, founded in 2005, is a system semiconductor design solution corporation that connects system semiconductor design companies (fabless) with contract manufacturing companies (foundries).